Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Thursday morning. The brokerage issued a buy rating on the biotechnology company’s stock.

Separately, Barclays dropped their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th.

Cellectis Trading Down 5.0 %

Cellectis stock opened at $1.33 on Thursday. The business has a 50 day moving average price of $1.61 and a two-hundred day moving average price of $1.89. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The stock has a market cap of $73.93 million, a price-to-earnings ratio of -1.02 and a beta of 3.06. Cellectis has a 12 month low of $1.32 and a 12 month high of $3.38.

Hedge Funds Weigh In On Cellectis

Hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN raised its holdings in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after buying an additional 12,500 shares in the last quarter. Millennium Management LLC bought a new stake in Cellectis during the 4th quarter worth approximately $962,000. Finally, B Group Inc. bought a new stake in Cellectis during the 4th quarter worth approximately $5,547,000. 63.90% of the stock is owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.